Study of Liver Safety from Statin Use in Adults Aged 18 to 85 with Neurological Conditions

What this Trial Is About

Researchers are investigating the liver safety of statin use among inpatients in the neurology department in China. This study uses both a cross-sectional design and a retrospective cohort study to analyze statin effects from different perspectives. The goal is to provide additional evidence-based guidance for clinical use of statins in patients with neurological conditions, including cerebrovascular disease, headache, dizziness, and vertigo. The research consists of two phases. First, a cross-sectional study examines the relationship between statin use before hospital admission and the initial liver enzyme levels of patients. Next, a retrospective cohort study divides patients who were not on statins prior to admission into two groups based on whether they started statins after admission. Liver enzymes such as aspartate aminotransferase AST and alanine aminotransferase ALT are measured four weeks after admission to assess liver safety. Participants are hospitalized adults aged 18 to 85 years with specific neurological diagnoses. Researchers review medical histories and liver enzyme tests, focusing on AST and ALT levels four weeks after admission. The study excludes patients with incomplete medical records, short prior statin use, malignant tumors, or blood diseases. The total participation involves data analysis from hospital records during the defined study period from June 2020 to February 2023.

Hepatic Safety of Statin Use in Neurology Inpatients